NASDAQ:WVE - Wave Life Sciences Stock Price, Forecast & News

Wave Life Sciences trades on the NASDAQ under the ticker symbol "WVE."

Wave Life Sciences Ltd (NASDAQ:WVE) announced its quarterly earnings results on Tuesday, November, 5th. The company reported ($1.48) EPS for the quarter, missing the Zacks' consensus estimate of ($1.34) by $0.14. The firm had revenue of $2.93 million for the quarter, compared to analyst estimates of $6.30 million. Wave Life Sciences had a negative net margin of 1,015.84% and a negative return on equity of 128.21%. View Wave Life Sciences' Earnings History.

Wave Life Sciences is scheduled to release their next quarterly earnings announcement on Monday, March 2nd 2020. View Earnings Estimates for Wave Life Sciences.

Wave Life Sciences will be holding an earnings conference call on Monday, March 2nd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

8 brokerages have issued twelve-month price objectives for Wave Life Sciences' stock. Their forecasts range from $10.00 to $65.00. On average, they expect Wave Life Sciences' stock price to reach $25.00 in the next twelve months. This suggests a possible upside of 157.2% from the stock's current price. View Analyst Price Targets for Wave Life Sciences.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Wave Life Sciences in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Wave Life Sciences.

Media headlines about WVE stock have trended very positive recently, InfoTrie reports. The research firm ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Wave Life Sciences earned a media sentiment score of 4.0 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Wave Life Sciences.

Wave Life Sciences saw a increase in short interest in January. As of January 31st, there was short interest totalling 6,440,000 shares, an increase of 46.4% from the January 15th total of 4,400,000 shares. Based on an average daily volume of 882,200 shares, the days-to-cover ratio is currently 7.3 days. Currently, 24.8% of the company's shares are short sold. View Wave Life Sciences' Current Options Chain.

Some companies that are related to Wave Life Sciences include Revance Therapeutics (RVNC), Odonate Therapeutics (ODT), NextCure (NXTC), Akebia Therapeutics (AKBA), Phibro Animal Health (PAHC), Enanta Pharmaceuticals (ENTA), Portola Pharmaceuticals (PTLA), Opko Health (OPK), Myovant Sciences (MYOV), Karyopharm Therapeutics (KPTI), Dermira (DERM), Kiniksa Pharmaceuticals (KNSA), Applied Therapeutics (APLT), Gossamer Bio (GOSS) and Cytokinetics (CYTK).

Based on aggregate information from My MarketBeat watchlists, some companies that other Wave Life Sciences investors own include Gilead Sciences (GILD), Exelixis (EXEL), Novavax (NVAX), TherapeuticsMD (TXMD), Aduro BioTech (ADRO), Crispr Therapeutics (CRSP), Sangamo Therapeutics (SGMO), Agile Therapeutics (AGRX), Cidara Therapeutics (CDTX) and Eyepoint Pharmaceuticals (EYPT).

Wave Life Sciences' stock is owned by many different of institutional and retail investors. Top institutional shareholders include ArrowMark Colorado Holdings LLC (2.89%), Janus Henderson Group PLC (2.34%), State Street Corp (1.40%), FMR LLC (0.61%), Point72 Asset Management L.P. (0.46%) and Spark Investment Management LLC (0.38%). Company insiders that own Wave Life Sciences stock include Chandra Vargeese, Chris Francis, Gregory L Verdine, Keith Regnante, Michael A Panzara, Paul Bolno and Ra Capital Management, Llc. View Institutional Ownership Trends for Wave Life Sciences.

WVE stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, FMR LLC, Spark Investment Management LLC, State Street Corp, New York State Common Retirement Fund, Bank of America Corp DE, Platinum Investment Management Ltd. and ProShare Advisors LLC. Company insiders that have sold Wave Life Sciences company stock in the last year include Chandra Vargeese, Gregory L Verdine, Michael A Panzara and Paul Bolno. View Insider Buying and Selling for Wave Life Sciences.

WVE stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Assenagon Asset Management S.A., Pictet Asset Management Ltd., Citigroup Inc., California Public Employees Retirement System, Amia Capital LLP, NJ State Employees Deferred Compensation Plan and Cubist Systematic Strategies LLC. View Insider Buying and Selling for Wave Life Sciences.

Shares of WVE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of WVE stock can currently be purchased for approximately $9.72.

Wave Life Sciences has a market capitalization of $333.30 million and generates $14.41 million in revenue each year. The company earns $-146,650,000.00 in net income (profit) each year or ($5.06) on an earnings per share basis. Wave Life Sciences employs 250 workers across the globe.View Additional Information About Wave Life Sciences.

The official website for Wave Life Sciences is http://www.wavelifesciences.com/.

Wave Life Sciences' mailing address is 7 STRAITS VIEW #12-00 MARINA ONE EAST TOWER, SINGAPORE U0, 018936. The company can be reached via phone at 65-6236-3388 or via email at [email protected]